(12) Patent Application Publication (10) Pub. No.: US 2016/0368929 A1 Janganati Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 20160368929A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0368929 A1 Janganati et al. (43) Pub. Date: Dec. 22, 2016 (54) MELAMPOMAGNOLIDE B DERVATIVES (22) Filed: Sep. 1, 2016 (71) Applicants: Venumadhav Janganati, Little Rock, Related U.S. Application Data AR (US); Narsimha Reddy Penthala, (62) Division of application No. 14/537,389, filed on Nov. Little Rock, AR (US); Peter A. Crooks, 10, 2014, now Pat. No. 9,469,650. Little Rock, AR (US); Craig T. Jordan, (60) Provisional application No. 61/901,714, filed on Nov. Rochester, NY (US) 8, 2013. (72) Inventors: Venumadhav Janganati, Little Rock, Publication Classification AR (US); Narsimha Reddy Penthala, Little Rock, AR (US); Peter A. Crooks, (51) Int. C. Little Rock, AR (US); Craig T. Jordan, C07D 49.3/04 (2006.01) Rochester, NY (US) (52) U.S. C. CPC ................................... C07D 493/04 (2013.01) (73) Assignees: The Board of Trustees of the University of Arkansas, Little Rock, (57) ABSTRACT AR (US); University of Rochester, The present disclosure provides derivatives of melampo Rochester, NY (US) magnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for (21) Appl. No.: 15/254,849 treating cancer in humans. Patent Application Publication Dec. 22, 2016 Sheet 1 of 9 US 2016/0368929 A1 xxii. ::::::::::::::::::::::::::::: i. www.ss 3. O Concentration (ity F.G. 1 Patent Application Publication Dec. 22, 2016 Sheet 2 of 9 US 2016/0368929 A1 -------------------------------------------------------.3. Concentratia (ii) x . «xx-x Y-8 'Ys: x - FG 2 Patent Application Publication Dec. 22, 2016 Sheet 3 of 9 US 2016/0368929 A1 : :............................................................:::::::::::::::::::::::::::::::::::::::::::::::::::::::ww.xxx f :- ×xy 3-8. xx -: 3.:s 3-33 Patent Application Publication Dec. 22, 2016 Sheet 4 of 9 US 2016/0368929 A1 { s: : (centratic FG 4 Patent Application Publication Dec. 22, 2016 Sheet 5 of 9 US 2016/0368929 A1 Concentration aw F.G. 5 i. Concentration uv F.G. 6 Patent Application Publication Dec. 22, 2016 Sheet 6 of 9 US 2016/0368929 A1 s 2 Concentration uM) FIG 7 Patent Application Publication Dec. 22, 2016 Sheet 7 of 9 US 2016/0368929 A1 ***************** ·*** .............…..,&&************************&&- Patent Application Publication Dec. 22, 2016 Sheet 8 of 9 US 2016/0368929 A1 88: 88: w88. : s X: :: Ex xx s s: & & : :^ AqeA 33% Patent Application Publication Dec. 22, 2016 Sheet 9 of 9 US 2016/0368929 A1 3. x wing: s & s s s s &qeA 33% US 2016/0368929 A1 Dec. 22, 2016 MELAMPOMAGNOLIDE B DERVATIVES (I) CROSS REFERENCE TO RELATED X APPLICATIONS 0001. This application is a divisional of U.S. Ser. No. ls R1 14/537,389, filed Nov. 10, 2014, which claims the benefit of U.S. provisional application No. 61/901,714, filed Nov. 8, 2013, the disclosures of which are hereby incorporated by reference in their entirety. O GOVERNMENTAL RIGHTS O O or 0002 This invention was made with government support X (II) under Grant No. CA158275 awarded by the National Insti tutes of Health (NIH). The government has certain rights to the invention. 1s, FIELD OF THE INVENTION 0003. This disclosure generally relates to a series of R2 melampomagnolide B (MMB) derivatives, including car bamate, thiocarbamate and carbonate derivatives of MMB. O These compounds exhibit potent anticancer activity. O O BACKGROUND OF THE INVENTION 0007 wherein: 0004 Parthenolide (PTL), an abundant sesquiterpene lac 0008 X is O or S; tone found in the medicinal herb feverfew (Tanacetum 0009 R' and R are independently selected from the parthenium), has undergone intense pharmacological group consisting of NRR, OR, O-alkyl research, especially for its antileukemic properties. Initial NRR', SR, S-alkyl-NRR, alkyl-C(O)NR'R'', biomechanistic studies of PTL and its derivatives indicate and -alkyl-R: that the compound promotes apoptosis by inhibiting the 0010 R is selected from the group consisting of NF-kB transcription factor complex, thereby downregulat hydrocarbyl, substituted hydrocarbyl, and R: ing antiapoptotic genes under NF-kB control. PTL and its I0011) R' is selected from the group consisting of derivatives may also interfere with glutathione function, hydrogen, hydrocarbyl, and substituted hydrocarbyl: specifically glutathione's ability to sequester reactive oxy I0012 R is an optionally substituted nitrogen-contain gen species. In culture, PTL induces robust apoptosis of ing heterocyclic ring; primary acute myeloid leukemia (AML) cells in culture. To 0013 one or more of RandR may form part of a ring overcome poor water-solubility, PTL may be derivatized or ring system chosen from the group consisting of with an alkylamino, which can convert into water-soluble heterocyclic, Substituted heterocyclic, and combina salts. A series of fluorinated amino derivatives of PTL tions thereof, and exhibit activity in antiproliferative assays in HL-60 (human I0014) when R is hydrogen, R is selected from the promyelocytic leukemia) cells. PTL has also been the source group consisting of alkyl, R. and substituted hydro of several antileukemic compounds arising from chemical carbyl having at least one hydroxyl or R. modification of the PTL molecule. 0015. Another aspect of the disclosure provides a process 0005 Melampomagnolide B (MMB), a melampolide for preparing a compound comprising Formula (I) or (II). originally isolated from Magnolia grandiflora, is an anti The process comprises (a) contacting a compound compris leukemic sesquiterpene with properties similar to those of ing Formula (III) with a triazole reagent to form a compound PTL. MMB has been synthesized via selenium oxide oxi comprising Formula (IV). The process continues with (b) dation of the C10 methyl group of PTL, resulting in a contacting the compound of Formula (IV) with a compound concomitant conversion of the geometry of the C9-C10 comprising formula R'—H to form a compound comprising double bond from trans to the cis geometry. MMB contains Formula (I). The process is according to the following a primary OH group, providing a point of attachment for reaction scheme: derivatives with increased water solubility, bioavailability, and tissue targeting. Phase 1 clinical data from dimethyl aminoparthenolide (DMAPT), a synthetic aminopartheno OH lide derivative, indicated improved bioavailability and lon ger in vivo half-lifes for PTL and MMB derivatives with triazole increased water solubility. -e- reagent SUMMARY OF THE INVENTION 0006 Briefly, therefore, one aspect of the present disclo Sure encompasses compounds comprising Formula (I) or (III) (II): US 2016/0368929 A1 Dec. 22, 2016 -continued AML 052308 cell line as a function of concentration (uM) R6 and percentage of cell viability. (0028 FIG. 2 shows the antileukemic activity of PTL, MMB, JMV 57, JMV 58, JMV 59, and JMV 61 against the ) y AML 052308 cell line as a function of concentration (uM) YN R7 and percentage of cell viability. (0029 FIG. 3 shows the 24-hour M9's percentage of live 1s, cells relative to untreated cells for PTL, MMB, JMV 2-5, JMV 2-16, JMV 2-40, JMV 2-49, JVM 2-35, JVM 2-41, and JVM 95 as a function of concentration (uM). R-H 0030 FIG. 4 shows the 24-hour M9's percentage of live cells relative to untreated cells for PTL, MMB, JMV 2-26, JMV 2-31, JMV 2-4, JMV 86, JVM 90, and JVM 96 as a O O O function of concentration (LM). 0031 FIG. 5 shows the antileukemic activity of PTL, (IV) MMB, and JMV 88 against the M9 ENL cell line as a X function of concentration (LM) and percentage of cell viabil ity at 24 hours. 1. 0032 FIG. 6 shows the antileukemic activity of PTL, MMB, and JMV 88 against the AML 123009 cell line as a function of concentration (LM) and percentage of cell viabil ity. 0033 FIG. 7 shows the antileukemic activity of PTL, MMB, and JMV 88 against the AML 100510 cell line as a O O O function of concentration (LM) and percentage of cell viabil ity at 24 hours. (I) 0034 FIG. 8 shows structures of PTL (1), DMAPT fumarate (2) and MMB (3). 0016 wherein: (0035 FIG.9 shows the cytotoxic mechanism of action of 0017 X is O or S; MMB analogs. I0018) R' is selected from the group consisting of 0036 FIG. 10 shows a graph demonstrating the anti NRR, OR, O-alkyl-NR'R'', SR, leukemic activity of carbamate and carbonate derivatives of S-alkyl-NRR, alkyl-C(O)NR'R'', -alkyl-C(O)R, melampomagnolide B against M9 ENL cells. and -alkyl-R: 0037 FIG. 11 shows a graph demonstrating the anti (0019 R is selected from the group consisting of leukemic activity of Succinic amide derivatives of melam hydrocarbyl, substituted hydrocarbyl, and R: pomagnolide B against M9 ENL cells. 0020 R. R. and R7 are independently selected from the group consisting of hydrogen, hydrocarbyl, and DETAILED DESCRIPTION OF THE substituted hydrocarbyl: INVENTION I0021 R is an optionally substituted nitrogen-contain ing heterocyclic ring; 0038 Provided herein are carbamate, thiocarbamate, and (0022) one or more of RandR may form part of a ring carbonate conjugates of MMB, which may be synthesized or ring system chosen from the group consisting of via an intermediate prepared by reacting MMB with carbo heterocyclic, Substituted heterocyclic, and combina nylditriazole to afford MMB triazole (JVM 2-16, Example tions thereof, and 10). This triazole intermediate may be reacted with various 0023 when R is hydrogen, R is selected from the heterocyclic amines, including, for example, imidazole, group consisting of alkyl, R. and substituted hydro morpholine, piperidine, pyrrolidine, triazole, and pyridine, carbyl having at least one hydroxyl or R. to afford the corresponding carbamate conjugate. To prepare carbonate conjugates of MMB, MMB triazole may be 0024 Yet another aspect of the disclosure provides a reacted with hydroxyl-containing compounds, including method for inhibiting growth of a cancer cell.